

Rapid Medical - Abstract

- **Investment Rational**

Rapid Medical is a fast growing, global MedTech company committed to developing endovascular solutions that allow physicians to advance interventional capabilities offering treatments for more patients. With the company's proprietary and differentiated technology platform, which has yielded best-in-class clinical data it is positioned to unlock and penetrate new opportunities in the large and underpenetrated neurovascular market.

- **Business Strategy**

Rapid Medical has 3 FDA cleared products and 4 products which are CE marked. These products are sold through the company's expanding commercial network in the US and EU. The products are sold at premium pricing and are already generating gross margins of more than 80%.

- **Core Technology**

The two core pillars of the company underpinning its innovative product portfolio are a unique, advanced 3D braiding technology and an unprecedented remote device adjustability.

- **Product Profile/Pipeline**

Over 40 peer-reviewed papers published underscore the company's product technology. In the recently completed TIGER pivotal trial, Tigertriever yielded superior efficacy, clinical outcomes and safety and outperformed predicate ischemic stroke devices from Medtronic and Stryker. Tigertriever13 is the smallest ischemic stroke device on the planet and is the only device with a delivery profile of 0.4 millimeter.

- ⊖ **What's Next?**

Disruptive Tigertriever13 enables 1st-ever treatment for Medium Vessel Occlusions comprising ~40% of all strokes. It is cleared in Europe for MVO's and has been utilized in more than 1,000 procedures. A pivotal trial is FDA approved and underway in the US. Moreover, the company is rapidly expanding its commercial foot-print and has an attractive financial profile with multiple growth levers.